Targeting the LPI/GPR55 Axis in MAFLD and MASH: Novel Insights, Therapeutic Strategies and Future Directions
Abstract Metabolic dysfunction‐associated fatty liver disease (MAFLD), recently redefined from non‐alcoholic fatty liver disease (NAFLD), highlights the central role of…